Soleo Health scales to meet demand for approved Alzheimer’s drug
By HME News Staff
Updated 12:01 PM CDT, Mon July 10, 2023
FRISCO, Texas – Soleo Health says it’s prepared to address anticipated increases in demand for LEQEMBI on the heels of the U.S. Food and Drug Administration giving the Alzheimer’s drug full approval on July 7. Earlier this year, Soleo Health was selected by Eisai as the specialty pharmacy distribution partner for LEQEMBI. At the time, the drug had only received fast-track approval from the FDA. “LEQEMBI represents an important advancement in the ongoing fight to treat Alzheimer’s Disease,” said Drew Walk, CEO of Soleo Health. “We are already administering LEQEMBI to patients nationwide and have received significant interest from many more, as well as the Alzheimer’s community. We expect interest to dramatically increase with the full FDA approval and have scaled our national clinical network and operations to meet impending demand.” Soleo Health will provide treatment to patients prescribed LEQEMBI at any of its 35-plus ambulatory infusion centers (AICs) nationwide or in their homes. The company will support patients through its Alzheimer’s Disease Therapeutic Care Management Center (TCMC), staffed with specially trained interdisciplinary teams comprised of highly experienced therapy-care pharmacists, registered nurses, reimbursement specialists and patient care ambassadors.
Comments